THE CONSTANT CURRENT IN THERAPEUTICS.

Aptamer Therapeutics in Cancer: Current and Future

Aptamer-related technologies represent a revolutionary advancement in the capacity to rapidly develop new classes of targeting ligands. Structurally distinct RNA and DNA oligonucleotides, aptamers mimic small, protein-binding molecules and exhibit high binding affinity and selectivity. Although their molecular weight is relatively small-approximately one-tenth that of monoclonal antibodies-thei...

Antisense therapeutics in oncology: current status

There is increasing progress in translational oncology and tremendous breakthroughs have been made as evidenced by preclinical and clinical trials. Data obtained from high-throughput technologies are deepening our understanding about the molecular and gene network in cancer cells and rapidly emerging in vitro and in vivo evidence is highlighting the role of antisense agents as specific inhibito...

Measurement of electrogenic-pump current in Aplysia neurones with constant-current and constant-voltage techniques.

1. The responses of the abdominal and pleural giant cells to warming and cooling were studied using constant-current and constant-voltage techniques. 2. The potential change upon warming from about 7 degrees C to 22 degrees C was reversed by application of maintained inward current. The reversal potential was -77 +/- 12 mV. 3. The membrane conductance increased with warming, but was not affecte...

Current Progress of RNA Aptamer-Based Therapeutics

Aptamers are single-stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due to their stable three-dimensional structure. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging, biomarker discovery, target validation, therapeutics, and drug delivery. Due to their high specificity and binding affinity, ...

Bioconjugate Therapeutics: Current Progress and Future Perspective.